Erica Schleifman
Senior Director - Cancer Biomarker Development AstraZeneca
Erica Schleifman is the Senior Director of Cancer Biomarker Development at AstraZeneca, where she leads a cross-functional team that supports the strategic planning and integration of circulating tumor DNA (ctDNA) analyses across all solid tumor trials. This work enables real-time disease monitoring to accelerate and strengthen decision-making. A solution-driven leader, she brings extensive experience building and guiding cross-functional collaborations that translate complex science into measurable clinical and commercial impact.
Prior to joining AstraZeneca, Erica held various roles of increasing responsibility and leadership in precision medicine at Roche/Genentech leading enterprise-wide initiatives and novel companion diagnostic projects. She is known for aligning diverse teams around shared priorities, breaking down silos and delivering innovative solutions that advance precision oncology.
She holds a Ph.D. in Genetics from Yale University and a Bachelors of Biological Sciences from Carnegie Mellon University
Seminars
- Turning ctDNA and MRD signals into faster, higher confidence go/no-go decisions across modalities
- Cutting years and cost from development by replacing slow endpoints with early molecular insight
- Making liquid biopsy work in the real world: global logistics, scalability, and ROI for sponsors
